medication tirzepatide (Zepbound, Mounjaro): Weight Loss, Diabetes, Dosage & Side Effects How the weight loss drug

Find out more about the shifts in purchasing habits.

Understanding biomarkers, genetic predispositions, and individualized medical evaluation can support informed conversations with providers

others argue that the rules are out of date

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity

growth, despite international market hurdles.

Axonal damage permanent disability over time